Could tempeh and vitamin d ease IBD symptoms?
NCT ID NCT07656233
First seen Jun 19, 2026 · Last updated Jun 19, 2026
Summary
This study tested whether taking tempeh powder (a source of isoflavones) and vitamin D3 daily for 8 weeks could improve vitamin D levels, reduce inflammation, and boost quality of life in people with inflammatory bowel disease (IBD). Fifty adults with ulcerative colitis or Crohn's disease took part. The goal was to see if these supplements, added to standard care, offer extra benefits.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS (UC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia
Jakarta Pusat, DKI Jakarta, 10430, Indonesia
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tempeh isoflavone and vitamin D3 supplements
What this could lead to
If it works, this could point toward a simple dietary supplement to help manage inflammation and improve quality of life in people with inflammatory bowel disease.
What could go wrong
This is a small, early-stage trial with only 50 participants and no blinding, so results may not be reliable or apply to everyone. Supplements may not significantly change disease outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.